An interventional study of Ketogenic diet, food delivery and education and Standard diet, food delivery and education in Diabetes Mellitus, Type 1, sponsored by Boston Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 5 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-04-24.
Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 190 open to participants now, 257 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 525th largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 63 that started in 2024, is one of 614 with no phase, reaches primary completion later than 189 of the 256 other live ones, and was the 1,216th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →190 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 31–75 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 5–40
Stanford University · Sites in United States
Ages 18–60 · Healthy volunteers
Wayne State University · Sites in United States
Ages 16–20
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 5 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,458 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 206 · Phase 2 267 · Phase 3 167 · Phase 4 74
First in 1983; this study’s year is marked. 63 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 52 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 40 across the 1,242 interventional studies, 63 across the 203 observational. Of the 1,118 that completed or were terminated, 563 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
398 of 1,458 have an industry lead sponsor. The 10 most frequent:
Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
Boston Children's Hospital has 9 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
115 of the studies in Diabetes Mellitus, Type 1 with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT06334133Phase 3vTv TherapeuticsCadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | 2027-04 |
| NCT07056699Phase 3The University of Texas Health Science Center at San AntonioSGLT2i, Pioglitazone, and Ketone Production in T1D | 2027-06-01 |
Add all 115 to your calendar (.ics) → With an account.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test the effects of a ketogenic diet on the progression and control of type 1 diabetes in children with newly diagnosed diabetes. The main questions to answer are:
Participants will receive a combination of free meals, groceries, micronutrient supplements, and intensive diet and diabetes education for 9 months.
Comparison will be made between a ketogenic vs standard diet.
Type I diabetes is caused by an autoimmune destruction of insulin producing β-cells in the pancreas, resulting in absolute insulin deficiency. In the first months after diagnosis, a small number of β-cells typically remain and, by producing insulin, significantly improve diabetes control and reduce disease burden.
Preliminary data suggest that this early disease stage entitled the "honeymoon period" might be extended by a ketogenic diet, which would provide a major therapeutic advantage and may reduce chronic disease burden.
To test the hypothesis that a ketogenic vs. standard diet will extend the honeymoon period and improve diabetes control in children, the researchers are conducting a study employing education and food deliveries of a ketogenic or standard diet to children and their families. Fifty-two children aged 5 to 12 years with newly diagnosed diabetes will participate. Children will be assigned by chance (randomized) to receive either a ketogenic or a standard diet for 9 months. Chances to be assigned to either diet are 50:50 like a coin flip, and 26 children will participate in each diet arm.
Participants will receive a combination of free meals, groceries, micronutrient supplements, and intensive diet and diabetes education throughout the 9 months. Continuous glucose monitoring (CGM) and diaries will be used for cloud-based data collection. Bi-weekly data downloads and remote check-ins will be performed to assess dietary intake, satisfaction with diet and study procedures, and possible safety concerns. Participants are instructed to measure blood ketone levels with their home ketone meter anytime blood glucose levels exceed a safety threshold and to call the study physician for persistent low glucose levels or ketones above diet specific safety thresholds.
Study visits are held at at baseline, 1, 5, and 9 months to collect height, weight, stool and blood samples for hormones, metabolites and inflammatory biomarkers. At each visit, an intravenous catheter (IV) will be placed to collect fasting blood samples, followed by a liquid test meal (protein shake) and collection of four additional blood samples from the IV over the course of two hours. Prior to each visit, participants will collect stool samples at home using provided kits. In addition, participants and their families may be invited to participate in a semi-structured interview, and online questionnaires to asses their food intake, experience with the diet, diabetes care burden and complications, and general well-being and quality of life. They may also be invited to participate in a follow-up visit to evaluate long-term effects after 24 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diet will be high in protein and healthy fats and comprise meat, fish, fibrous vegetables, nuts, dairy, and berries. Macronutrient composition will be \~ 5% carbohydrate, 20% protein, 70% fat. Participants will receive a daily multi-vitamin, magnesium supplement, and supplemental salt (bouillon cubes) to ascertain micronutrient sufficiency and help with transition to the diet.
Other: Ketogenic diet, food delivery and education
The diet will be consistent with prevailing dietary guidelines and recommendations and contain meat, fish, grains, vegetables, fruit and dairy. At least 50% of grain-based products will be whole grains. Meats will be primarily lean, and dairy products will be fat-free or low-fat. Macronutrient composition will be \~50% carbohydrate (\<10% added sugars), 20% protein, 30% fat. Participants will receive a daily multi-vitamin supplement to ascertain micronutrient sufficiency.
Other: Standard diet, food delivery and education
Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.
Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.
Decline in Beta-cell Function
Change in C-peptide 2-h area under the curve after a mixed-meal tolerance test (ΔCP).
Time frame: Change over 1, 5, and 9 months, corrected for baseline
Time in Range (TIR) 70-180 mg/dl
From continuous glucose monitoring (CGM) - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.
Time frame: Over 9 months and optional at 24 months
Duration of Clinical Diabetes Remission
Calculated based on percent children with insulin dose corrected HbA1c (IDAA1c) \<9.
Time frame: 1, 5, 9, and optional at 24 months
Time in low Range (TIR) <70 mg/dl
From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.
Time frame: Over 9 months and optional at 24 months
Time in very low Range (TIR) <55 mg/dl
From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.
Time frame: Over 9 months and optional at 24 months
Time in high Range (TIR) >180 mg/dl
From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation 2-week increments.
Time frame: Over 9 months and optional at 24 months
Time in very high Range (TIR) >250 mg/dl
From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.
Time frame: Over 9 months and optional at 24 months
Average Blood Glucose
From CGM - will be computed throughout study participation in 2-week increments.
Time frame: Over 9 months and optional at 24 months
Coefficient of Glycemic Variation (CV)
From CGM - will be computed by dividing glucose standard deviation by glucose average throughout study participation in 2-week increments.
Time frame: Over 9 months and optional at 24 months
Mean Amplitude of Glycemic Excursions (MAGE)
From CGM - will be computed using published formula throughout study participation in 2-week increments.
Time frame: Over 9 months and optional at 24 months
Total Daily Insulin Dose
From insulin administration device uploads - will be computed in units per kg throughout study participation in 2-week increments.
Time frame: Over 9 months and optional at 24 months
HOMA-IR (Homeostatic Model Assessment for Insulin Resistance)
Calculated from fasting blood draw \[fasting insulin (µU/ml) × fasting plasma glucose (mg/dl)\]/405.
Time frame: 1, 5, 9, and optional at 24 months
BMI
Weight divided by height squared.
Time frame: 1, 5, 9, and optional at 24 months
Lipid panel
Fasting blood - total, LDL and HDL cholesterol, and triglycerides.
Time frame: 1, 5, 9, and optional at 24 months
HDL to Triglyceride Ratio
Fasting blood
Time frame: 1, 5, 9, and optional at 24 months
Lipoprotein Subfractions
Fasting blood
Time frame: 1, 5, 9, and optional at 24 months
Inflammasome, targeted
Interleukins 1β, 17, 23, 6, 10; high sensitivity c-reactive protein; tumor necrosis factor α, interferon gamma
Time frame: 1, 5, 9, and optional at 24 months
Microbiome, targeted and untargeted
Extraction and sequencing will be performed by Qiagen PowerSoil DNA extraction using Qiagen's DNeasy 96 PowerSoil Pro QIAcube HT Kit (480), followed by whole genome sequencing (WGS) using a miniaturized version of the NEBNext Ultra FS II method.
Time frame: 1, 5, 9, and optional at 24 months
Metabolome, targeted and untargeted
Blood samples will be processed using liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR). The LC-MS analyses will be carried out on a Sciex triple quadrupole mass spectrometer couple to an Exion ultra-performance LC system. The targeted analysis will utilize the Biocrates Q500 targeted metabolomics assay which quantifies more than 500 metabolites over 26 chemical classes (Biocrates Inc., Innsbruck, Austria). Data processing to yield metabolite concentrations in micromolar units will utilize the Biocrates MetIDQ software. The NMR data will be acquired on a Bruker Avance NEO 700 MHz NMR equipped with a TCI cryoprobe and a SampleXPress automatic sample changer. The data will be processed using the Chenomx NMR Processor and Profiler packages (Chenomx, Edmonton, CA) to yield quantitative data in millimolar units.
Time frame: 1, 5, 9, and optional at 24 months
Problem Areas in Diabetes (PAID-Ped) - child
Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate greater burden.
Time frame: 1, 5, 9, and optional at 24 months
Problem Areas in Diabetes (PAID-PR) - parent
Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate greater burden.
Time frame: 1, 5, 9, and optional at 24 months
Pediatric Quality of Life (PEDSQL) General Module - parent
Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate better quality of life.
Time frame: 1, 5, 9, and optional at 24 months
Pediatric Quality of Life (PEDSQL) General Module - child
Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate better quality of life.
Time frame: 1, 5, 9, and optional at 24 months
Pediatric Quality of Life (PEDSQL) Diabetes Module - parent
Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate less problems.
Time frame: 1, 5, 9, and optional at 24 months
Pediatric Quality of Life (PEDSQL) Diabetes Module - child
Validated questionnaire, scored according to published standards. Scores range 0-100, higher scores indicate less problems.
Time frame: 1, 5, 9, and optional at 24 months
Child Eating Disorder Examination Questionnaire (ChEDE-Q8)
Validated questionnaire, scored according to published standards. Scores range 0-42, higher scores are worse.
Time frame: 1, 5, 9, and optional at 24 months
Perceptions on Diet Management of Diabetes
Questionnaire to assess participants' and caregivers' perceptions of the influence of the diet on their diabetes management.
Time frame: 1, 5, 9, and optional at 24 months
Qualitative patient perspectives, interview - parent
Interviews will be held with children and caregivers separately after implementation and completion of the intervention.
Time frame: optional at 9 months
Qualitative patient perspectives, interview - child
Interviews will be held with children and caregivers separately after implementation and completion of the intervention.
Time frame: optional at 9 months
Time in tight Range (TIR) 70-140 mg/dl
From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.
Time frame: Over 9 months and optional at 24 months
Time above tight Range (TIR) >140 mg/dl
From CGM - percent time spent in the specified glycemic target range will be computed throughout study participation in 2-week increments.
Time frame: Over 9 months and optional at 24 months
BOHB (beta-hydroxybutyrate), fasting blood concentration
Obtained at daily increasing to weekly intervals as effect modifier of beta-cell function.
Time frame: Over 9 months and optional at 24 months
Growth
Safety Measure - Height standard deviation score will be calculated from serial height measurements obtained during study visits using CDC age and sex specific references.
Time frame: 1, 5, 9, and optional at 24 months
Growth velocity
Safety Measure - Growth velocity will be calculated from serial height measurements obtained during study visits.
Time frame: 1, 5, 9, and optional at 24 months
Weigh-gain
Safety Measure - Weight SDS and gain will be calculated from serial weight measures obtained during study visits with calibrated scale.
Time frame: 1, 5, 9, and optional at 24 months
Confirmed Ketoacidosis
Safety Measure - Defined by elevated BOHB, blood pH \<7.3 and serum bicarbonate \<15. Rates will be computed as total number of events divided by total patient years of follow-up.
Time frame: Over 9 months and optional at 24 months
Severe Hypoglycemia
Safety Measure - Defined as blood glucose \< 55 mg/dl and requiring glucagon or resulting in seizure or coma. Rates will be computed as total number of events divided by total patient years of follow-up.
Time frame: Over 9 months and optional at 24 months
Diabetes Related Emergency Visits
Safety Measure - Rates will be computed as total number of events divided by total patient years of follow-up.
Time frame: Over 9 months and optional at 24 months
Diabetes Related Hospitalizations
Safety Measure - Rates will be computed as total number of events divided by total patient years of follow-up.
Time frame: Over 9 months and optional at 24 months
Study termination for disordered eating
Safety Measure - ChEDE-Q8 diagnostic score with clinical confirmation. Total number of events.
Time frame: Over 9 months
Study termination for growth deceleration
Safety Measure - Undesired weight loss or significant deceleration in longitudinal growth may warrant termination of study participation. Total number of events will be computed.
Time frame: Over 9 months
Study termination for dyslipidemia
Safety Measure - LDL \>200 mg/dl will trigger review of additional risk factors and may prompt diet modification to lower intake of saturated fats. If persistent, study participation may be terminated. Total number of events will be computed.
Time frame: Over 9 months
Plan to share: Yes — Upon publication, de-identified raw data for each original article will be uploaded to the appropriate an NIH maintained repository.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Study protocol and statistical analysis plan will be shared prior to enrollment of the first participant. De-identified data will be shared upon manuscript publication.
Access criteria: Data will be downloadable.
Started May 2024 (actual). Primary completion is estimated for Apr 2028, 46 months after the start.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 46 months is above that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.